PremiumThe FlyAvenue Therapeutics reports Q3 EPS $(1.92) , consensus (94c) Avenue Therapeutics Incentive Plan Awards Key Executives Allarity appoints Alex Epshinsky as CFO PremiumThe FlyAvenue Therapeutics trading resumes Avenue Therapeutics trading halted, volatility trading pause Avenue Therapeutics trading halted, news pending PremiumPre-EarningsATXI Earnings Report this Week: Is It a Buy, Ahead of Earnings? Avenue Therapeutics Shareholders Approve Stock Capacity Hike Avenue Therapeutics announces publication of preclinical data of BAER-101